Evaluation of Short-term Safety and Use Patterns of an Electronic Nicotine Delivery System

Evaluation of Plasma Nicotine, Carbon Monoxide, Heart Rate, Craving and Withdrawal After Acute Use of the NJOY King E-Cigarette in the Clinic, Following a One-Week Actual Use Pilot Study

Electronic Nicotine Delivery Systems (ENDS), commonly referred to as electronic cigarettes have gained in popularity over the last several years. The technology used to manufacture ENDS has been evolving rapidly with a variety of delivery mechanisms, nicotine content, e-liquids and flavorings. Only in the last few years have researchers begun to examine the health risks and benefits, nicotine blood levels, patterns of use, likability, and craving and withdrawal relief of ENDS. These studies have shown great variability in nicotine delivery, effects on heart rate, and relief of craving or withdrawal among various ENDS brands among tobacco cigarette smokers.

This study will test a new generation ENDS, the NJOY King Bold (NJOY, Scottsdale, AZ). It is a single use unit that resembles a traditional cigarette and delivers approximately 150 puffs. The cartridge inside contains 26 milligrams of nicotine.

Our primary objective is to evaluate the short-term effects of using the NJOY Kings ENDS on heart rate, carbon monoxide and blood nicotine levels and well as on craving for cigarettes and nicotine withdrawal. Our secondary objective is to evaluate the subject's usage patterns for cigarettes and NJOY King ENDS during a one-week period in which they can use each freely.

The study includes three visits to the clinic spaced approximately one week apart. Subjects who pass the screening visit will return to the clinic for Visit 2 in which they will sample the NJOY King ENDS for about 20 minutes before taking home enough to last till Visit 3, one week later. They will be instructed to use as many or as few as they like during the week. Subjects will keep a daily diary of number of tobacco cigarettes smoked and number of e-cigarette puffs taken. Subjects will return to the clinic for Visit 3 after 12 hours of abstinence from any form of nicotine in order to assure that they have no nicotine left in their bloodstream. Eligible subjects will then participate in two series of 10 puffs of NJOY Kings spaced one hour apart. During the 2.5 hours of the testing day, the following will be measured: 1) heart rate, 2) carbon monoxide, 3)blood will be sampled for nicotine levels, 4) craving for cigarettes and nicotine withdrawal symptoms will be assessed.

Study Overview

• Status: Unknown
• Conditions: Nicotine Dependence
• Intervention / Treatment: Other: NJOY King 26 mg nicotine Electronic Nicotine Delivery System

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Burbank, California, United States, 91505
      • LA Clinical Trials

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 61 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy cigarette smokers
2. Not trying or planning to quit
3. >10 factory-produced cigarettes/day for previous year
4. Breath carbon monoxide level of >10 ppm at screening

Exclusion Criteria:

1. Pregnancy or lactation
2. Abuse of drugs other than tobacco
3. Use of any prescription psychoactive medications within 14 days
4. Use of ENDS within 14 days
5. Use of any nicotine replacement within 30 days

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NJOY King 26 mg nicotine Electronic Nicotine Delivery System	Other: NJOY King 26 mg nicotine Electronic Nicotine Delivery System; NJOY® King ENDS, menthol or nonmenthol, ad libitum use for 1 week NJOY® King ENDS, menthol or nonmenthol, 2 series of puffs, with a 30-second interpuff interval in each series and 1 hour between the first puff in each series.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in blood nicotine levels	Note: Visit 3 can occur up to 28 days after the Screening Visit	Change from baseline at Visit 3 to 5, 10, 15 and 30 minutes after each of two series, spaced one hour, apart of 10 puff from the NJOY King at Visit 3
Change in average cigarettes smoked per day	Subjects will have a one weeks supply of NJOY Kings to use as they like. Mean cigarettes per day during the "actual use week" will be compared to the mean cigarettes per day for the baseline week (which is one week before the "actual use" week)	The baseline week compared to the week testing the NJOY Kings in the "real world"
Average NJOY Kings puffs used per day	Mean number of puffs per day of NJOY King ENDS used during Day 1 through Day 6 of the actual use week which can begin 1 to 3 weeks after the Screening Visit	Day 1 through Day 6 of the of testing the NJOY Kings in the "real world"

Collaborators and Investigators

• Sponsor: LA Clinical Trials
• Collaborators: NJOY, Inc.
• Investigators: Principal Investigator: MITCHELL NIDES, Ph.D., LA Clinical Trials

Study record dates

Study Major Dates

• Study Start: April 1, 2013
• Primary Completion (Anticipated): July 1, 2013
• Study Completion (Anticipated): July 1, 2013

Study Registration Dates

• First Submitted: July 2, 2013
• First Submitted That Met QC Criteria: July 10, 2013
• First Posted (Estimate): July 12, 2013

Study Record Updates

• Last Update Posted (Estimate): July 12, 2013
• Last Update Submitted That Met QC Criteria: July 10, 2013
• Last Verified: July 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Substance-Related Disorders; Tobacco Use Disorder; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Agents; Ganglionic Stimulants; Nicotinic Agonists; Cholinergic Agonists; Nicotine
• Other Study ID Numbers: NJ-001 LACT; ISRCTN95345566 (Other Identifier: ISRCTN)